Transplantation for chronic myelogenous leukemia: yes, no, maybe so…an Oregon perspective (original) (raw)
Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ . STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002; 20: 325–334. ArticleCASPubMed Google Scholar
Druker BJ, Tamura S, Buchdunger E, Ohno S et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996; 2: 561–566. ArticleCASPubMed Google Scholar
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F et al. Imatinib (Gleevec™) results in sustained hematologic and cytogenetic responses among chronic-phase chronic myeloid leukemia (CML) failing interferon-alpha (IFN) – up to 31-month follow-up of 454 patients on phase II study. Blood 2002; 100: 94a (Abstr. 347). Google Scholar
Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937. ArticleCASPubMed Google Scholar
Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539. ArticleCASPubMed Google Scholar
O'Dwyer ME, Mauro MJ, Blasdel C et al. Lack of cytogenetic response is an adverse prognostic factor for relapse of chronic phase CML patients treated with imatinib mesylate (STI571). Blood 2001; 98: 137a (Abstr. 579). Google Scholar
Cortes J, Talpas M, O'Brien et al. Significance of lack of early cytogenetic (CG) response after therapy with imatinib mesylate in relation to later achievement of major or complete CB response in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood 2002; 100: 787a (Abstr. 3113). Article Google Scholar
Marin D, Bua M, Marktel S et al. The combination of cytogenetic response after 6 months treatment with STI571 and the presence of cytopenias in patients with CML in chronic phase resistant to or intolerant of interferon-alfa defines four different prognostic groups. Blood 2001; 98: 137a (Abstr. 3514). Article Google Scholar
Sneed TB, Kantarjian HM, Talpaz M et al. Significance of myelosuppression (MS) during the course of therapy with imatinib in patients with chronic myelogenous leukemia (CML) in chronic phase. Blood 2002; 100: 787a (Abstr. 3110). Google Scholar
Mauro MJ, O'Dwyer ME, Kurilik G et al. Risk factors for myelosuppression in chronic phase CML patients treated with imatinib mesylate (STI571). Blood 2001; 98: 139a (#585). Google Scholar
O'Brien SG, Guilhot F, Larson R et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 11: 994–1004. Article Google Scholar
Hughes T, Kaeda J, Branford S et al. Molecular responses to Imatinib (STI571) or Interferon+Ara-C as initial therapy for CML: results in the IRIS study. Blood 2002; 100: 93a (Abstr. 345). Google Scholar
Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63: 789–799. CASPubMed Google Scholar
Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Wrtiting Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–858. ArticleCASPubMed Google Scholar
Baccarani M, Trabacchi E, Bassi S et al. Results of a phase II trial testing a combination of imatinib and pegylated α2b Interferon in PH+ chronic myeloid leukemia in early chronic phase. The early cytogenetic response is significantly risk related. By the Italian Cooperative Study Group on CML. Blood 2002; 100: 24a (Abstr. 348). Google Scholar
Horwitz MM, Rowlings PA, Passweg JR . Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996; 17 (Suppl. 3): S5–S6. Google Scholar
Kolb HJ, Mittermuller J, Clemm C, Holler E . Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465. CASPubMed Google Scholar
Collins RH, Spielberg O, Drobyski W et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444. ArticlePubMed Google Scholar
Guglielmi C, Arcese W, Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial dose. Blood 2002; 100: 397–405. ArticleCASPubMed Google Scholar
Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036–2043. CASPubMed Google Scholar
Lee SJ, Kuntz KM, Horowitz MM et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia. Ann Intern Med 1997; 127: 1080–1088. ArticleCASPubMed Google Scholar
Hansen JA, Gooley TA, Martin PF et al. Bone marrow transplants from unrelated donors of patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962–968. ArticleCASPubMed Google Scholar
Morton AJ, Gooley T, Hansen JA et al. Association between pretransplant Interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998; 92: 394–401. CASPubMed Google Scholar
Giralt S, Szydlo R, Goldman JM et al. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. Blood 2000; 95: 410–415. CASPubMed Google Scholar
Hehlmann R, Hochhaus A, Jans-Jochem K et al. Interferon-α before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999; 94: 3668–3677. CASPubMed Google Scholar
Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087–1092. ArticleCASPubMed Google Scholar
Or R, Shapira MY, Resnick I et al. Nonmyeloablative allogeneic stem cell tranpslantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 444–445. Article Google Scholar
Sandmaier BM, Hegenbart U, Shizuru J et al. Nonmyeloablative hematopoietic stem cell transplantation (SCT) from HLA-identical siblings for treatment of chronic myelogenous leukemia (CML): induction of molecular remissions. Blood 2001; 98: 371b (Abstr. 5259). Google Scholar
Crawley CR, Lalancette M, Szydlo R et al. Reduced intensity conditioned allografts for chronic myeloid leukaemia: a study from the chronic leukaemia working party of the EBMT. Blood 2002; 781a (Abstr. 3089).
Hehlmann R, Berger U, Hochhaus A et al. Randomized comparison of early allogeneic related stem cell transplantation vs IFN-based therapy in newly diagnosed chronic myelogenous leukemia: first interim analysis of the German CML Study III. Blood 2001; 98: 728a (Abstr. 3036). Google Scholar
Olavarria E, Craddock C, Dazzi F et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002; 99: 3861–3862. ArticleCASPubMed Google Scholar
Kantarjian HM, O'Brien S, Cortes JE et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590–1595. CASPubMed Google Scholar
Chambon-Paulas C, Cony-Makhoul P, Giraudier S et al. Glivec (STI571) treatment for chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (SCT): a report of the French experience (On behalf of the SFGM and FILMC). Blood 2001; 98: 140 (Abstr. 587). Article Google Scholar
Wassman B, Pfeifer H, Scheuring U et al. Glivec (STI571) in the treatment of patients with chronic myeloid leukemia (CML) relapsing in accelerated or blastic phase after allogeneic stem cell transplantations. Blood 2001; 98: 140 (Abstr. 588). Article Google Scholar
Soiffer RJ, Galinsky I, DeAngelo D et al. Imatinib mesylate (Gleevec) for disease relapse following allogeneic bone marrow transplantation. Blood 2001; 98: 400 (Abstr. 682). Google Scholar
Ullmann AJ, Beck J, Koble K et al. Clinical and laboratory evaluation of patients treated with STI571 (Gleevec) after allogeneic and syngeneic stem cell transplantation with relapsed Philadelphia chromosome-positive leukemia. Blood 2001; 98: 401 (Abstr. 1685). Google Scholar
Hernandez-Boluda J-C, Carreras E, Cervantes F et al. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with α-interferon. Haematologica 2002; 87: 17–22. CASPubMed Google Scholar
Olavarria E . Autotransplant for chronic myelogenous leukemia: is it useful? Haematologica 2002; 87: 3–5. PubMed Google Scholar
Carella AM, Lerma E, Corsetti MT et al. Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999; 93: 1534–1539. CASPubMed Google Scholar
McGlave PB, De Fabritiis P, Deisseroth A et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343: 1486–1488. ArticleCASPubMed Google Scholar
Maziarz RT, Chauncey TR, Capdeville R et al. Growth factor mobilization of CD34+ PBSC in CML patients treated with imatinib (STI571). Blood 2001; 98: 738a (Abstr. 3078). Google Scholar
Choudhury A, Gajewski JL, Liang JC et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome positive chronic myelogenous leukemia. Blood 1997; 89: 1133–1142. CASPubMed Google Scholar
Kantarjian HM, Cortes J, O'Brien S et al. Effect of increasing imatinib mesylate (STI571) dose from 400 mg to 800 mg daily on outcome of patients (pts) with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML CP). Blood 2001; 98: 137a (Abstr. 576). Google Scholar
Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ . Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000; 96; 3195–3199. CASPubMed Google Scholar
Perkins C, Kim CN, Fang G, Bhalla KN . Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL . Blood 2000; 95: 1014–1022. CASPubMed Google Scholar
Porosnicu M, Nimmanapalli R, Nguyen D et al. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells. Leukemia 2001; 15: 772–778. ArticleCASPubMed Google Scholar
La Rosée P, Johnson K, Corbin A et al. In-vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib resistant Bcr-Abl positive cell lines, submitted.
Hoover R, Mahon FX, Melo JV et al. Overcoming STI571 resistance with the Farnesyltransferase inhibitor SCH6636. Blood 2001; 98: 617a (Abstr. 2585). Google Scholar
Martine G, Philippe R, Michel T et al. Imatinib (Gleevec®) and cytarabine (Ara-C) is an effective regimen in Philadelphia (Ph)-positive chronic myelogenous leukaemia (CML) chronic phase (CP) patients (pts). Blood 2002; 100: 95a (Abstr. 351). Google Scholar
Mauro MJ, O'Dwyer ME, Stone RM et al. Preliminary evaluation of the combination of imatinib mesylate (Gleevec) with low dose Ara-C as initial therapy for newly diagnosed chronic phase CML. Blood 2002; 100: 165a (#617). Google Scholar
O'Dwyer ME, Mauro MJ, Kuyl J et al. Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML. Blood 2001; 98: 846a (#3513). Google Scholar
O'Brien S, Vallance SE, Craddock T et al. PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia. Blood 2001; 98: 846a (Abstr. 3512). Google Scholar
Mauro MJ, Deininger MW, O'Dwyer ME et al. Phase I/II study of arsenic trioxide (Trisenox) in combination with imatinib mesylate (Gleevec, STI571) in patients with Gleevec-resistant chronic myelogenous leukemia in chronic phase. Blood 2002; 100: 781a (#3090). Google Scholar
Gotlib J, Dugan K, Katamneni U et al. Phase I/II study of farnesyltransferase inhibitor R115777 (Zarnestra) in patients with myeloproliferative disorders (MPDs): preliminary results. ASCO 2002; 4a Volume 21, Part 1 of 2 (#14).
Goldman JM, Druker BJ . Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039–2042. ArticleCASPubMed Google Scholar
Mauro MJ, Maziarz RT, Kuyl J et al. Increasing levels of detectable leukemia in imatinib treated CML patients with previously undetectable or very low levels of Bcr-Abl. ASCO 2003, submitted.
Gotlib J, Cao T, Jones C et al. Serial real-time quantitative RT-PCR monitoring reveals frequent and rapid relapses after molecular remissions in chronic phase (CP) CML patients treated with imatinib mesylate (GLEEVEC™). Blood 2002; 100: 547a (#2151). Article Google Scholar
O'Dwyer ME, Mauro MJ, Kurilik G et al. The impact of clonal evolution on response to imatinib mesylate (Gleevec) in accelerated phase CML. Blood 2002; 100: 1628–1633. ArticleCASPubMed Google Scholar
O'Dwyer M, Gatter K, Loriaux M et al. The demonstration of clonal abnormalities in Philadelphia chromosome negative cells following imatinib mesylate induced major cytogenetic response in patients with chronic myeloid leukemia. Leukemia 2003; 17: 481–487. ArticleCASPubMed Google Scholar
Bumm T, Mueller C, Leiblein S et al. Restoration of polyclonal hematopoiesis in most CML patients in complete cytogenetic remission to imatinib but rapid emergence of clonal cytogenetic abnormalities in Ph-negative cells in a subset of patients. Blood 2002; 100: 164a (#613). Google Scholar
Medina J, Kantarjian H, Talpaz M et al. Chromosomal abnormalities in Philadelphia chromosome (Ph) negative metaphases appearing during treatment with imatinib mesylate in patients (pts) with Ph positive chronic myeloid leukemia (CML) in chronic phase (CP). Blood 2002; 100: 368a (#1423). Google Scholar
Deininger MW, Schleuning M, Sayer HG et al. Allografting after imatinib therapy: no evidence for increased transplant-related mortality and favorable results in patients transplanted in remission; a retrospective study by the EBMT. Blood 2002; 100: 783a (#3097). Google Scholar
Shimoni A, Kroger N, Zander A et al. Imatinib mesylate (STI571) in preparation for allogenic hematopoetic stem cell transplantation and donor leukocyte infusions in patients with Philadelphia positive acute leukemias. Leukemia 2003; 17: 290–297. ArticleCASPubMed Google Scholar